RESUMEN
BACKGROUND: Both highly specialized heart centres and less specialized hospitals care for patients with implantable ICDs/CRT-Ds with remote monitoring. OBJECTIVE: To investigate potential differences in patient treatment according to centre's ICD implantation volume. METHODS: Based on their 2012 ICD/CRT-D implantation volume, centres enrolled in the NORDIC ICD trial in Germany were assigned to one of three groups: high- (HV, n= 345), medium- (MV, n= 340) or low-volume (LV, n= 189). RESULTS: The HV-centres had a significant higher CRT-D proportion (41.7%; LV: 36.5%; MV: 23.2%; Pðððððð< 0.001), significant shorter median procedure duration (49 min; MV: 58 min; LV: 60 min; Pðððððð< 0.001) but significant longer median hospital stay (4 days; MV and LV: 3 days; Pðððððð< 0.001) compared to MV- and LV-centres. The X-ray exposure was shorter in MV/HV-centres (MV: 3.4 min; HV: 3.6 min; LV: 5.5 min; Pðððððð< 0.001). Only 3.5% (LV: 2.6%; HV: 3.5%; MV: 4.1%) patients received at least one delivered inappropriate shock and 2.5% (HV: 2.0%; LV: 2.6%; MV: 2.9%) patients had withheld inappropriate ICD shocks without subsequent inappropriate shock delivery within 24.5 months of median follow-up. CONCLUSION: Implantation volume-dependent differences were observed in the device selection, procedure duration and x-ray exposure duration. Remote monitoring in combination with adequate response pattern prevented imminent inappropriate shocks in all three groups.
RESUMEN
INTRODUCTION: Transradial access (TRA) has become the primary route for coronary angiography (CAG) and percutaneous coronary interventions (PCI). Recently a new puncture site more distally in the area of the anatomical snuffbox has been described. With this multicenter registry, we wish to demonstrate the feasibility and safety of the distal radial access (dRA). METHODS: Between December 2018 and May 2019 all patients with a planned CAG or PCI via dRA in three cardiology centers in Germany were entered into this registry. Procedural data, puncture success, crossover rate and complications were registered. Proximal and distal radial artery patency were examined by ultrasound within 48 h. RESULTS: A total of 327 patients were enrolled (mean age: 69 ± 12 years, 69% male gender, 49% PCI), in 5 cases bilateral distal puncture was performed. Puncture success, defined as completed sheath placement was high (N = 316/332, 95%) and the crossover rate was low (27/332, 8%). The rate of proximal radial artery occlusion after 1-48 h was low (2/332 1%), the rate of occlusion at the distal puncture site was also very low (3/332, 1%). Major complications were not encountered. CONCLUSION: Coronary angiography and interventions via the distal transradial access in the area of the anatomical snuffbox can be performed with a high rate of success and safety. This data suggests a reduced rate of radial artery occlusion compared to previously reported data after cannulation via the standard forearm radial artery puncture site. Randomized studies are needed to further investigate these results. TRIAL REGISTRATION: This study was registered in the German registry for clinical trials: DRKS00017110, retrospectively on 07.May 2019.
RESUMEN
AIMS: The diagnostic approach to idiopathic giant-cell myocarditis (IGCM) is based on identifying various patterns of inflammatory cell infiltration and multinucleated giant cells (GCs) in histologic sections taken from endomyocardial biopsies (EMBs). The sampling error for detecting focally located GCs by histopathology is high, however. The aim of this study was to demonstrate the feasibility of gene profiling as a new diagnostic method in clinical practice, namely in a large cohort of patients suffering from acute cardiac decompensation. Methods and Results: In this retrospective multicenter study, EMBs taken from n = 427 patients with clinically acute cardiac decompensation and suspected acute myocarditis were screened (mean age: 47.03 ± 15.69 years). In each patient, the EMBs were analyzed on the basis of histology, immunohistology, molecular virology, and gene-expression profiling. Out of the total of n = 427 patient samples examined, GCs could be detected in 26 cases (6.1%) by histology. An established myocardial gene profile consisting of 27 genes was revealed; this was narrowed down to a specified profile of five genes (CPT1, CCL20, CCR5, CCR6, TLR8) which serve to identify histologically proven IGCM with high specificity in 25 of the 26 patients (96.2%). Once this newly established profiling approach was applied to the remaining patient samples, an additional n = 31 patients (7.3%) could be identified as having IGCM without any histologic proof of myocardial GCs. In a subgroup analysis, patients diagnosed with IGCM using this gene profiling respond in a similar fashion to immunosuppressive therapy as patients diagnosed with IGCM by conventional histology alone. Conclusions: Myocardial gene-expression profiling is a promising new method in clinical practice, one which can predict IGCM even in the absence of any direct histologic proof of GCs in EMB sections. Gene profiling is of great clinical relevance in terms of a) overcoming the sampling error associated with purely histologic examinations and b) monitoring the effectiveness of therapy.
RESUMEN
This report outlines the long-term outcome after successful sealing of a coronary perforation with a covered stent in a patient with aspirin allergy.
Asunto(s)
Aspirina/farmacología , Vasos Coronarios/lesiones , Enfermedad Iatrogénica , Intervención Coronaria Percutánea/efectos adversos , Politetrafluoroetileno , Stents/efectos adversos , Lesiones del Sistema Vascular/diagnóstico , Anciano , Materiales Biocompatibles Revestidos/efectos adversos , Angiografía Coronaria , Vasos Coronarios/diagnóstico por imagen , Tolerancia a Medicamentos , Femenino , Humanos , Inhibidores de Agregación Plaquetaria/farmacología , Lesiones del Sistema Vascular/etiologíaRESUMEN
BACKGROUND: Atrial fibrillation (AF) is a common disease and can lead to cardioembolic stroke. Stroke prevention according to the CHA2DS2VASc score is achieved via oral anticoagulation. In recent years, interventional occlusion of the left atrial appendage (LAA) has become a common alternative. Besides showing non-inferiority in large trials compared with warfarin interventional LAA occlusion can lead to serious adverse events with most of them occurring peri-interventionally. CASE SUMMARY: A 75-year-old man with AF and recurrent gastrointestinal bleedings was referred for an interventional closure of the LAA. The intervention was successful with an ABBOTT® Amulet device. Four months later, the patient had to be resuscitated. Return of spontaneous circulation occurred after 10 min. On hospital arrival, echocardiography revealed a pericardial tamponade and 2 L of blood were drained. A coronary angiogram revealed a lesion with active leakage of contrast agent in the proximal circumflex artery. The patient was transferred to the cardiac surgery department immediately. Intra-operatively a perforation of the tissue at the basis of the LAA close to the left main coronary artery was discovered. The occluder was excised and the LAA was closed by endocardial sutures. DISCUSSION: In this report, we review the literature concerning interventional LAA occlusion and the reported cases of LAA perforation. Retrospectively, it remains unclear whether the perforation caused the resuscitation or was induced by it. To our knowledge, this is the first reported case of a laceration of a coronary artery by an occlusion device.
RESUMEN
BACKGROUND: In heart failure (HF) patients with implantable cardioverter defibrillators (ICD) or cardiac resynchronisation therapy defibrillators (CRT-D), remote monitoring has been shown to result in at least non-inferior outcomes relative to in-clinic visits. We aimed to provide further evidence for this effect, and to assess whether adding telephone follow-ups to remote follow-ups influenced outcomes. METHODS: InContact was a prospective, randomised, multicentre study. Subjects receiving quarterly automated follow-up only (telemetry group) were compared to those receiving personal physician contact. Personal contact patients were further divided into those receiving automated follow-up plus a telephone call (remote+phone subgroup) or in-clinic visits only. RESULTS: Two hundred and ten patients underwent randomisation (telemetry n = 102; personal contact n = 108 [remote+phone: n = 53; visit: n = 55]). Baseline characteristics were comparable between groups and subgroups. Over 12 months, 34.8% of patients experienced deterioration of their Packer Clinical Composite Response, with no significant difference between the telemetry group and personal care (p > 0.999), remote+phone (p = 0.937) or visit (p = 0.940) patients; predefined non-inferiority criteria were met. Mortality rates (5.2% overall) were comparable between groups and subgroups (p = 0.832/p = 0.645), as were HF-hospitalisation rates (11.0% overall; p = 0.605/p = 0.851). The proportion of patients requiring ≥1 unscheduled follow-up was nominally higher in telemetry and remote+phone groups (42.2 and 45.3%) compared to the visit group (29.1%). Overall, ≥ 1 ICD therapy was delivered to 15.2% of patients. CONCLUSION: In HF patients with ICDs/CRT-Ds, quarterly remote follow-up only over 12 months was non-inferior to regular personal contact. Addition of quarterly telephone follow-ups to remote monitoring does not appear to offer any clinical advantage. TRIAL REGISTRATION: clinicaltrials.gov: NCT01200381 (retrospectively registered on September 13th 2010).
Asunto(s)
Desfibriladores Implantables , Cardioversión Eléctrica/instrumentación , Insuficiencia Cardíaca/terapia , Tecnología de Sensores Remotos/instrumentación , Telemetría/instrumentación , Anciano , Cardioversión Eléctrica/efectos adversos , Cardioversión Eléctrica/mortalidad , Alemania , Insuficiencia Cardíaca/diagnóstico , Insuficiencia Cardíaca/mortalidad , Insuficiencia Cardíaca/fisiopatología , Humanos , Persona de Mediana Edad , Visita a Consultorio Médico , Valor Predictivo de las Pruebas , Estudios Prospectivos , Teléfono , Factores de Tiempo , Resultado del TratamientoRESUMEN
BACKGROUND: Long-term continuous monitoring detects short-lasting, subclinical atrial fibrillation (SCAF) in approximately one-third of older individuals with cardiovascular conditions. The relationship between SCAF, its progression, and the development of heart failure (HF) is unclear. OBJECTIVES: This study examined the relationship between progression from shorter to longer SCAF episodes and HF hospitalization. METHODS: Subjects in ASSERT (Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial) were ≥65 years old, had history of hypertension, no prior clinical AF, and an implanted pacemaker or defibrillator. We examined patients whose longest SCAF episode during the first year after enrollment was >6 min but ≤24 h (n = 415). Using time-dependent Cox models, we evaluated the relationship between subsequent development of SCAF >24 h or clinical AF and HF hospitalization. RESULTS: Over a mean follow-up of 2 years, 65 patients (15.7%) progressed to having SCAF episodes >24 h or clinical AF (incidence 8.8% per year). Older age, greater body mass index, and longer SCAF duration within the first year were independent predictors of SCAF progression. The rate of HF hospitalization among patients with SCAF progression was 8.9% per year compared with 2.5% per year for those without progression. After multivariable adjustment, SCAF progression was independently associated with HF hospitalization (hazard ratio [HR]: 4.58; 95% confidence interval [CI]: 1.64 to 12.80; p = 0.004). Similar results were observed when we excluded patients with prior history of HF (HR: 7.06; 95% CI: 1.82 to 27.30; p = 0.005) or when SCAF progression was defined as development of SCAF >24 h alone (HR: 3.68; 95% CI: 1.27 to 10.70; p = 0.016). CONCLUSIONS: In patients with a pacemaker or defibrillator, SCAF progression was strongly associated with HF hospitalization.
Asunto(s)
Fibrilación Atrial/epidemiología , Fibrilación Atrial/fisiopatología , Progresión de la Enfermedad , Insuficiencia Cardíaca/epidemiología , Insuficiencia Cardíaca/fisiopatología , Marcapaso Artificial/tendencias , Anciano , Anciano de 80 o más Años , Fibrilación Atrial/diagnóstico , Femenino , Estudios de Seguimiento , Insuficiencia Cardíaca/diagnóstico , Humanos , Masculino , Marcapaso Artificial/efectos adversos , Factores de RiesgoRESUMEN
BACKGROUND: Recent studies have shown that cryoablation and radiofrequency (RF) ablation are comparable with regard to success rates and safety in the treatment of common atrial flutter (AFL). Long-term success requires persistence of bidirectional conduction block (BCB) in the inferior cavotricuspid isthmus (CTI). OBJECTIVE: The purpose of this study was to determine the persistence of BCB in a prospective randomized multicenter trial of the two ablation techniques. METHODS: A total of 191 patients were randomized to RF ablation or cryoablation of the CTI using an 8-mm-tip catheter. In all patients, BCB was defined as the ablation end-point. Primary end-point of the study was nonpersistence of achieved BCB and/or ECG-documented relapse of common AFL within 3-month follow-up. RESULTS: Acute success rates were 91% (83/91) in the RF group and 89% (80/90) in the cryoablation group (P = NS). Invasive follow-up after 3 months with repeated electrophysiologic study was available for 60 patients in the RF group and 64 patients in the cryoablation group. Persistent BCB could be confirmed in 85% of the RF group versus 65.6% of the cryoablation group. The primary end-point was achieved in 15% of the RF group and 34.4% of the cryoablation group (P = .014). As a secondary end-point, pain perception during ablation was significant lower in the cryoablation group (P <.001). CONCLUSION: Persistence of BCB in patients treated with cryoablation reinvestigated after 3 months is inferior to that patients treated with RF ablation, as evidenced by the higher recurrence rate of common AFL seen in this study.
Asunto(s)
Aleteo Atrial/cirugía , Ablación por Catéter , Criocirugía , Sistema de Conducción Cardíaco/cirugía , Válvula Tricúspide/cirugía , Vena Cava Inferior/cirugía , Anciano , Electrofisiología Cardíaca , Femenino , Sistema de Conducción Cardíaco/fisiopatología , Humanos , Masculino , Persona de Mediana Edad , Factores de Tiempo , Resultado del TratamientoAsunto(s)
Desfibriladores Implantables , Diagnóstico por Computador/métodos , Electrocardiografía Ambulatoria/instrumentación , Electrocardiografía Ambulatoria/métodos , Taquicardia Supraventricular/diagnóstico , Taquicardia Supraventricular/prevención & control , Taquicardia Ventricular/diagnóstico , Taquicardia Ventricular/prevención & control , Diagnóstico por Computador/instrumentación , Diagnóstico Diferencial , Humanos , Sensibilidad y Especificidad , Terapia Asistida por Computador/métodosRESUMEN
BACKGROUND: Few data are available to define the circuits in ventricular tachycardia (VT) after myocardial infarction and the conduction time (CT) through the zone of slow conduction (SCZ). This study assessed the CT of the SCZ and identified different reentrant circuits. METHODS: During VTs, concealed entrainment (CE) was attempted. The SCZ was identified by a difference between postpacing interval (PPI) and VT cycle length (VTcl) < or =30 ms. Since the CT in the normally conducting part of the VT circuit is constant during VT and CE, a CE site within the reentrant circuit with (S-QRS)/PPI > or = 50% was classified as an inner reentry in which the entire circuit was within the scar, and a CE site with (S-QRS)/PPI < 50% as a common reentry in which part of the circuit was within the scar and part out of the scar. RESULTS: CE was achieved in 20 VTs (12 patients). Six VTs (30%) with a (S-QRS)/PPI > or =50% were classified as inner reentry and 14 VTs (70%) with a (S-QRS)/PPI <50% during CE mapping as common reentry. The EG-QRS interval (308 +/- 73 ms vs 109 +/- 59 ms, P < 0.0001) was significantly longer and the incidence of systolic potentials higher (4/6 vs 0/12, P < 0.001) in the inner reentry group. For the 14 VTs with a common reetry, the CT of the SCZ was 348 +/- 73 ms, while the CT in the normal area was 135 +/- 50 ms. CONCLUSION: According to the proposed classification, 30% of VTs after myocardial infarction had an entire reentrant circuit within the scar. In VTs with a common reentrant circuit, the CT of the SCZ is approximately four times longer than the CT in the normal area, accounting for more than 70% of VTcl.
Asunto(s)
Mapeo del Potencial de Superficie Corporal/métodos , Diagnóstico por Computador/métodos , Infarto del Miocardio/complicaciones , Infarto del Miocardio/diagnóstico , Taquicardia por Reentrada en el Nodo Atrioventricular/diagnóstico , Anciano , Femenino , Humanos , Masculino , Reproducibilidad de los Resultados , Sensibilidad y EspecificidadRESUMEN
BACKGROUND: Substrate modification guided by CARTO system has been introduced to facilitate linear ablation of ventricular tachycardia (VT) after myocardial infarction (MI). However, there is no commonly accepted standard approach available for drawing these ablation lines. Therefore, the aim of the present study was to practically refine this time consuming procedure. METHODS: Substrate modification was performed in 23 consecutive patients with frequent VTs after MI using the CARTO system. The initial target site (ITS) for ablation was identified by pace mapping (PM) during sinus rhythm and/or entrainment pacing (EM) during VT. According to the initial target site, two approaches were used. The initial target site in approach one has a similar QRS morphology as VT and an interval from the stimulus to the onset of QRS complex (S-QRS) of = 50 ms during PM in sinus rhythm or a difference of the post pacing interval and VT cycle length = 30 ms during concealed entrainment pacing of VT; The initial target site in approach two has an similar QRS morphology as VT and an S-QRS of < 50 ms during PM in sinus rhythm. RESULTS: Overall, 50 lines were performed with a length of (35 +/- 11) mm. Procedure time averaged (232 +/- 56) minutes, fluoroscopy time (10 +/- 8) minutes. Sixteen patients were initially involved into approach one. After completion of 3 +/- 1 ablation lines, no further VT was inducible in 13 patients. The remaining 3 patients were switched to use the alternative approach. However, in none of them the alternative approaches were successful. Approach two was initially used in 7 patients. After completion of 3 +/- 1 ablation lines, no further VT was inducible in only 2 patients. The remaining 5 patients were switched to approach one, which resulted in noninducibility of VT in 4 of them. The initial successful rate was significantly higher in the group of approach one compared to that in the group of approach two (13/16 patients vs 2/7 patients, P = 0.026). CONCLUSIONS: The approach for substrate modification of VT after MI can be optimized by identifying the appropriate initial target site with specific characteristics within the zone of slow conduction. The refined approach may facilitate linear ablation of VT, and further reduce the procedure and fluoroscopy time.
Asunto(s)
Mapeo del Potencial de Superficie Corporal/instrumentación , Ablación por Catéter/métodos , Infarto del Miocardio/complicaciones , Cirugía Asistida por Computador/métodos , Taquicardia Ventricular/cirugía , Anciano , Mapeo del Potencial de Superficie Corporal/métodos , Electrocardiografía , Femenino , Humanos , Masculino , Persona de Mediana Edad , Taquicardia Ventricular/fisiopatologíaRESUMEN
AIMS: Earlier ICD therapy included an electrophysiological study (EPS), an extensive defibrillation threshold test (DFT), and a pre-discharge test. Now that ICD-therapy is widely accepted, an EPS is no longer performed in most patients, extensive DFT-tests have been reduced to a minimum of two effective shocks and discharge tests have been discarded in most centres. However, it has never been demonstrated prospectively that this simplification is safe. METHODS AND RESULTS: The Quick-Implantable-Defibrillator (Quick-ICD) Trial was a prospective multi-centre trial, which randomized patients, who had survived a cardiac arrest (SCD) or an unstable ventricular tachycardia (VT), to two different clinical strategies: (a) The extensive strategy included an EPS, an extensive DFT-test, and a pre-discharge test; (b) In the simplified approach (quick strategy) the ICD was implanted without an EPS and a pre-discharge test. Two effective shocks during implantation at 21 J were sufficient. The primary endpoint of this trial was a cluster of adverse events related to the diagnostic approach and to ICD-therapy. One hundred and ninety patients were included, 97 randomized to the extensive-, 93 to the quick strategy. Mean follow-up was 12 +/- 7 months. Twenty-seven patients reached the endpoint in the quick group and 32 in the extensive group. During follow-up, the event-free survival was equal in the two study arms (test for equivalence, P = 0.0044). The initial hospital stay was significantly shorter in the quick population (8.4 +/- 4.7 vs. 11.2 +/- 7.4 days, P = 0.004) CONCLUSION: It is safe and cost-effective to implant an ICD without an EPS, an extensive DFT-, and a pre-discharge test in carefully selected patients after survived SCD or unstable VTs.
Asunto(s)
Desfibriladores Implantables , Paro Cardíaco/terapia , Taquicardia Ventricular/terapia , Anciano , Análisis Costo-Beneficio , Desfibriladores Implantables/efectos adversos , Cardioversión Eléctrica/economía , Cardioversión Eléctrica/métodos , Técnicas Electrofisiológicas Cardíacas/economía , Técnicas Electrofisiológicas Cardíacas/métodos , Determinación de Punto Final , Femenino , Estudios de Seguimiento , Paro Cardíaco/prevención & control , Humanos , Masculino , Persona de Mediana Edad , Modelos de Riesgos Proporcionales , Estudios Prospectivos , Taquicardia Ventricular/prevención & controlRESUMEN
BACKGROUND: Recently, substrate mapping (SM) has been described to facilitate catheter ablation of stable and unstable ventricular tachycardia (VT) after myocardial infarction. However, SM is time consuming with potential disadvantages of multiple ablation lines such as impairment of ventricular function or proarrhythmia. The aim of the present study was to delineate a stepwise approach to SM to shorten procedure time and limit the possibility of complications. METHODS: SM was performed in 14 infarct survivors referred for VT ablation using an electroanatomical mapping system (CARTO) to define infarct regions. A new stepwise approach for SM was designed as follows. The initial ablation site was identified by pace- and entrainment mapping in case of stable VT and by pace mapping only in case of unstable VT. Based on the CARTO voltage mapping, linear ablation was done from this site to the center of the scar and perpendicular to the boundary of the scar or to the mitral annulus. Additional lines were performed only when VT remained inducible. A maximum of 3 ablation lines were created during one procedure. RESULTS: A total of 57 VTs (21 stable, 36 unstable) were induced during the procedures. VT was no longer inducible after the first linear ablation in 2 patients, after the second linear ablation in 6 patients and after the third linear ablation in 3 patients. Either VT or ventricular fibrillation was still inducible at the end of the procedure in 3 patients. Procedure time averaged (291 +/- 85) minutes, fluoroscopy time (10 +/- 7) minutes. VT recurred in 3 patients. Following a second procedure in 2 patients, there were no further VT recurrences. Overall, there was a significant reduction in VT episodes 3 months after [median: 0, interquartile ranges (IQR): 0 - 1] compared with 3 months before ablation (median: 25, IQR: 16 - 105, P < 0.01). CONCLUSIONS: This stepwise approach to SM is effective in facilitating ablation of stable and unstable VT. It reduces procedure and fluoroscopy time, and may help to improve the risk-benefit ratio of VT ablation.
Asunto(s)
Ablación por Catéter/métodos , Infarto del Miocardio/complicaciones , Taquicardia Ventricular/cirugía , Anciano , Mapeo del Potencial de Superficie Corporal , Femenino , Humanos , Masculino , Persona de Mediana Edad , Factores de TiempoRESUMEN
CONTEXT: Implantable cardioverter defibrillator (ICD) therapy is effective but is associated with high-voltage shocks that are painful. OBJECTIVE: To determine whether amiodarone plus beta-blocker or sotalol are better than beta-blocker alone for prevention of ICD shocks. DESIGN, SETTING, AND PATIENTS: A randomized controlled trial with blinded adjudication of events of 412 patients from 39 outpatient ICD clinical centers located in Canada, Germany, United States, England, Sweden, and Austria, conducted from January 13, 2001, to September 28, 2004. Patients were eligible if they had received an ICD within 21 days for inducible or spontaneously occurring ventricular tachycardia or fibrillation. INTERVENTION: Patients were randomized to treatment for 1 year with amiodarone plus beta-blocker, sotalol alone, or beta-blocker alone. MAIN OUTCOME MEASURE: Primary outcome was ICD shock for any reason. RESULTS: Shocks occurred in 41 patients (38.5%) assigned to beta-blocker alone, 26 (24.3%) assigned to sotalol, and 12 (10.3%) assigned to amiodarone plus beta-blocker. A reduction in the risk of shock was observed with use of either amiodarone plus beta-blocker or sotalol vs beta-blocker alone (hazard ratio [HR], 0.44; 95% confidence interval [CI], 0.28-0.68; P<.001). Amiodarone plus beta-blocker significantly reduced the risk of shock compared with beta-blocker alone (HR, 0.27; 95% CI, 0.14-0.52; P<.001) and sotalol (HR, 0.43; 95% CI, 0.22-0.85; P = .02). There was a trend for sotalol to reduce shocks compared with beta-blocker alone (HR, 0.61; 95% CI, 0.37-1.01; P = .055). The rates of study drug discontinuation at 1 year were 18.2% for amiodarone, 23.5% for sotalol, and 5.3% for beta-blocker alone. Adverse pulmonary and thyroid events and symptomatic bradycardia were more common among patients randomized to amiodarone. CONCLUSIONS: Despite use of advanced ICD technology and treatment with a beta-blocker, shocks occur commonly in the first year after ICD implant. Amiodarone plus beta-blocker is effective for preventing these shocks and is more effective than sotalol but has an increased risk of drug-related adverse effects.Clinical Trials Registration ClinicalTrials.gov Identifier: NCT00257959.
Asunto(s)
Antagonistas Adrenérgicos beta/uso terapéutico , Amiodarona/uso terapéutico , Antiarrítmicos/uso terapéutico , Desfibriladores Implantables/efectos adversos , Sotalol/uso terapéutico , Antagonistas Adrenérgicos beta/administración & dosificación , Anciano , Amiodarona/administración & dosificación , Antiarrítmicos/administración & dosificación , Falla de Equipo , Femenino , Humanos , Masculino , Persona de Mediana Edad , Modelos de Riesgos Proporcionales , Sotalol/administración & dosificación , Fibrilación Ventricular/etiología , Fibrilación Ventricular/prevención & controlRESUMEN
BACKGROUND: Atrial tachycardia or flutter is common in patients after orthotopic heart transplantation. Radiofrequency catheter ablation to treat this arrhythmia has not been well defined in this setting. This study was conducted to assess the incidence of various symptomatic atrial arrhythmias and the efficacy and safety of radiofrequency catheter ablation in these patients. METHODS: Electrophysiological study and catheter ablation were performed in patients with symptomatic tachyarrhythmia. One Halo catheter with 20 poles was positioned around the tricuspid annulus of the donor right atrium, or positioned around the surgical anastomosis when it is necessary. Three quadripolar electrode catheters were inserted via the right or left femoral vein and positioned in the recipient atrium, the bundle of His position, the coronary sinus. Programmed atrial stimulation and burst pacing were performed to prove electrical conduction between the recipient and the donor atria and to induce atrial arrhythmias. RESULTS: Out of 55 consecutive heart transplantation patients, 6 males [(58 +/- 12) years] developed symptomatic tachycardias at a mean of (5 +/- 4) years after heart transplantation. Electrical propagation through the suture line between the recipient and the donor atrium was demonstrated during atrial flutter or during recipient atrium and donor atrium pacing in 2 patients. By mapping around the suture line, the earliest fragmented electrogram of donor atrium was assessed. This electrical connection was successfully ablated in the anterior lateral atrium in both patients. There was no electrical propagation through the suture line in the other 4 patients. Two had typical atrial flutter in the donor atrium which was successfully ablated by completing a linear ablation between the tricuspid annulus and the inferior vena cava. Two patients had atrial tachycardia which was ablated in the anterior septal and lateral donor atrium. There were no procedure-related complications. Patients were free of recurrent atrial tachyarrhythmias after a follow-up of (8 +/- 7) months. CONCLUSIONS: Four electrophysiological mechanisms have been found to contribute to the occurrence of symptomatic supraventricular arrhythmias following heart transplantation. Radiofrequency catheter ablation in patients with atrial flutter/tachycardia is feasible and safe after heart transplantation.
Asunto(s)
Aleteo Atrial/cirugía , Ablación por Catéter , Trasplante de Corazón/efectos adversos , Taquicardia Atrial Ectópica/cirugía , Adulto , Anciano , Aleteo Atrial/fisiopatología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Taquicardia Atrial Ectópica/fisiopatologíaRESUMEN
BACKGROUND: The Brugada syndrome is an autosomal dominant disorder characterized by life-threatening ventricular tachyarrhythmias due to cardiac conductance disturbance without structural heart disease. Mutations of the SCN5A gene cause either a reduction in cardiac Na(+) channel expression or alterations in channel-gating properties, leading to a reduction in Na(+) current amplitude. CASE REPORT: A 37-year-old patient presented after a syncopal spell preceded by dizziness. 6 years ago he had experienced similar symptoms. At that time, physical and clinical examination did not lead to a convincing diagnosis. The initial ECG showed typical signs of the Brugada syndrome with descending ST elevation in leads V(1) and V(2). The ECG changes could be observed over the next 3 days. Thereafter, ECG changes reversed to normal. Ultrasound examination did not show any signs of structural heart disease. During electrophysiological testing no sustained ventricular tachyarrhythmias were inducible. Molecular genetic analysis in this young patient revealed a mutation in the SCN5A gene. According to the patient's symptoms, an automatic cardioverter defibrillator (ICD) was implanted. CONCLUSION: A history of unexplained syncope in patients with a structurally normal heart should raise the suspicion of malignant arrythmias caused by primary arrythmogenic disorders. The diagnosis of Brugada syndrome can be concluded from typical ECG changes (i. e., incomplete right bundle branch block, ST elevation in leads V(1)-V(3)) accompanied by typical symptoms and a positive family history. To date, there is no effective therapy of the gene defect or its pathophysiological correlate available. Therefore, ICD therapy is recommended in symptomatic patients to prevent sudden cardiac death.
Asunto(s)
Síncope/etiología , Taquicardia Ventricular/complicaciones , Adulto , Aberraciones Cromosómicas , Análisis Mutacional de ADN , Muerte Súbita Cardíaca/prevención & control , Desfibriladores Implantables , Diagnóstico Diferencial , Genes Dominantes , Humanos , Masculino , Proteínas Musculares/genética , Canal de Sodio Activado por Voltaje NAV1.5 , Canales de Sodio/genética , Síncope/prevención & control , Síndrome , Taquicardia Ventricular/genética , Taquicardia Ventricular/terapiaRESUMEN
25 years after the first coronary artery patient received an implantable cardioverter defibrillator (ICD), many randomized controlled trials on prophylactic ICD therapy have been conducted. Taken together, these trials allow an evidence-based approach to primary prevention of sudden cardiac death in patients after a myocardial infarction. Patients with chronic ischemic cardiomyopathy, a long history of heart failure, and an ejection fraction of < or = 0.30 benefit from preventive device therapy and are thus candidates for prophylactic defibrillator implantation. For this purpose, a single-chamber device appears to be appropriate, since there have been no prospective studies showing convincing clinical benefit by adding an atrial lead. For similar patients who have additional intraventricular conduction delays, a biventricular ICD must be considered. However, this decision must be based on individual considerations until more data from prospective trials become available. Prophylactic ICD therapy should not be used in patients with recent myocardial infarction. There is convincing evidence that ICD benefit in coronary patients accrues after a considerable time having elapsed from the most recent infarct, presumably at least 6 months or perhaps longer.
Asunto(s)
Enfermedad de la Arteria Coronaria/mortalidad , Enfermedad de la Arteria Coronaria/terapia , Muerte Súbita Cardíaca/epidemiología , Muerte Súbita Cardíaca/prevención & control , Desfibriladores Implantables/estadística & datos numéricos , Cardioversión Eléctrica/estadística & datos numéricos , Medición de Riesgo/métodos , Comorbilidad , Humanos , Ensayos Clínicos Controlados Aleatorios como Asunto , Factores de Riesgo , Resultado del TratamientoRESUMEN
Sudden cardiac death (SCD), presumably because of ventricular tachyarrhythmias, remains one of the major challenges of contemporary cardiology. Major randomized controlled trials conducted in patients with coronary artery disease (CAD) with the aim of primary prevention of SCD are providing insights. Several large-scale studies have demonstrated that treatment with beta-blockers, angiotensin-converting enzyme inhibitors, aldosterone antagonists, and statins results not only in a reduction in all-cause mortality but specifically also in SCD. On top of this optimized pharmacological therapy, implantable cardioverter-defibrillators (ICD) further decrease the risk of overall and SCD mortality in carefully selected patient groups. The sum of these trials indicates, however, that the benefit associated with ICD therapy is most prominent in patients with chronic stable CAD. In contrast, patients early after myocardial infarction derive less benefit from ICD treatment, presumably because of a high competing risk of non-arrhythmic cardiovascular death. Optimized pharmacological therapy, together with the ICD, can substantially improve the prognosis of high-risk CAD patients.
Asunto(s)
Enfermedad de la Arteria Coronaria/tratamiento farmacológico , Muerte Súbita Cardíaca/prevención & control , Taquicardia Ventricular , Enfermedad de la Arteria Coronaria/complicaciones , Enfermedad de la Arteria Coronaria/mortalidad , Muerte Súbita Cardíaca/etiología , Femenino , Humanos , Masculino , Pronóstico , Ensayos Clínicos Controlados Aleatorios como Asunto , Factores de Riesgo , Taquicardia Ventricular/complicaciones , Taquicardia Ventricular/mortalidadRESUMEN
INTRODUCTION: Implantable cardioverter-defibrillator (ICD) therapy has been shown to improve survival in patients with structural heart disease and at high risk for life threatening ventricular arrhythmias. Whether elderly patients benefit from device therapy in a similar way as younger patients is largely unknown. METHODS: We retrospectively analyzed data from 375 consecutive ICD recipients with structural heart disease. Patients were divided into two groups, younger than 70 years at time of ICD implantation (group 1) or 70 years or older (group 2). Main outcome measures were time to death from any cause and time from first appropriate ICD therapy to death. RESULTS: Group 1 and 2 patients were comparable with respect to clinical presentation and average follow-up duration. In the elderly patient group, 78% received an ICD for secondary prevention versus 63% in group 1 (p = 0.007). During a mean follow-up period of 26.5 +/- 18.1 months, there was no significant difference in overall mortality among the two groups: 47 patients died, 34 (12.5%) of group 1 versus 13 (12.7%) of group 2. The average time to death was 28.4 +/- 16.7 vs 30.4 +/- 22.1 months after device implantation, respectively (p = ns). There was no difference in time from device implantation to first adequate ICD therapy and time from first appropriate ICD therapy to death among the two groups (p = ns). Device associated complications were comparable in both groups. CONCLUSIONS: Elderly ICD recipients had comparable survival rates and appropriate use of the ICD compared to younger individuals.